



VERDOT
2 Rue André Messenger
63200, Riom
France

Press Release

Riom, France | December 10, 2024

VERDOT Announces Carbon Compensation Initiative for 2025

- Over ten years of carbon footprint analysis and reduction for direct and indirect emissions
- Reaching one of the lowest levels in the industry with an average of 100 TeqCO₂ / M€ revenue
- Beginning in 2025, all chromatography column and stainless purification skids will have their specific manufacturing total carbon footprint established
- VERDOT manufactured products will have a carbon neutral footprint as the company will offset the remaining carbon emission impact



VERDOT is proud to announce its new Carbon Compensation Initiative, set to begin in 2025. This initiative aims to further reduce the company's carbon emissions by ensuring that each chromatography column and stainless purification skid is delivered as carbon neutral. The residual carbon footprint of these products will be systematically calculated and offset through a partnership with an accredited carbon credit provider.

For over ten years, VERDOT has been conducting carbon footprint analysis for direct (scope 1 and 2) and indirect emissions (scope 3), achieving one of the lowest carbon emission footprints in the bioprocessing manufacturing industry. Since 2014, the company has averaged a remarkable 100 TeqCO₂ per million euros revenue for both direct and indirect emissions.

The goal of this initiative is to bring awareness to the environmental impact of the industry and propose responsible and sustainable approaches for both VERDOT and its customers to reduce the carbon emissions produced. Over the last 10 years VERDOT has conducted continuous efforts in reducing its impact through eco-design, energy saving, and supplier selection.

VERDOT, 2 Rue André Messenger, Parc EERA, 63200 Riom | 04 73 33 70 70
VERDOT-biotechnologies.com

Société par actions simplifiée RCS Clermont-Ferrand 423 872 803
N° TVA intracommunautaire FR 25 423 872 803 - Siret 423 872 803 00030 – Code APE 2651B



VERDOT will partner with Stock CO2, a B Corp-certified operator specializing in the development of local carbon offsetting projects certified under the Bas-Carbone Label by the French Ministry of Ecological Transition.

Stock CO2 will certify that VERDOT's Carbon Compensation Initiative system meets the guidelines and criteria required to receive carbon credit.

"VERDOT has been at the forefront of sustainability with a low-environmental impact mindset from concept to manufacturing and supply. As pioneers in carbon emission reduction, we aim to lead by example and contribute to the industry's global effort to combat climate change," said Charles Ruban, CEO of VERDOT.

About VERDOT

VERDOT, established in 1950 and headquartered in Riom, France, stands at the forefront of downstream bioprocessing technology. VERDOT focuses on innovative purification solutions for the biopharmaceutical industry, including chromatography columns, and custom and standardized chromatography and tangential flow filtration (TFF) systems. VERDOT systems and columns are employed in the purification, separation and concentration of biomolecules such as monoclonal antibodies, vaccines, viral vectors (e.g., AAV and lentivirus), and mRNA-based therapeutics.

In addition to its technological expertise, VERDOT stands out for its commitment to sustainability, embedding environmentally conscious practices into its operations. The company's ongoing decarbonization efforts include over a decade of carbon footprint analysis, the development of energy-efficient manufacturing processes, and partnerships with leading conservation organizations to offset emissions.

VERDOT partners with industry leaders in biopharma, research and development, early-stage biotech, and contract development and manufacturing organizations (CDMOs), offering unparalleled expertise across the entire drug development workflow. From initial exploration to the manufacturing of market-ready biologics, VERDOT offers tailored, high-quality purification technologies that enable clients to accelerate time-to-market of groundbreaking therapies.

For more information about VERDOT, visit verdot-biotechnologies.com

Media contact

Imogen Quail, PR Manager, Ramarketing
imogen.quail@ramarketingpr.com

Brian Gerwe, Senior Director, Marketing and Product Management
brian.gerwe@verdot-biotechnologies.com